Findings of Research Misconduct
Notice Number: NOT-OD-16-104
Key Dates
Release Date: June 7, 2016
Related Announcements
None
None
Issued by
Department of Health and Human Services (DHHS)
Purpose
Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:
John G. Pastorino, Ph.D., Rowan University School of Osteopathic
Medicine: Based on an assessment conducted by Rowan University
School of Osteopathic Medicine (RUSOM), the Respondent's desire to
conclude the matter, and analysis conducted by ORI in its oversight
review, ORI found that Dr. John G. Pastorino, Associate Professor,
Department of Molecular Biology, RUSOM, engaged in research
misconduct in research supported by National Institute on Alcohol
Abuse and Alcoholism
(NIAAA), National Institutes of Health (NIH), grant R01 AA012897
and National Cancer Institute (NCI), NIH, grant R01 CA118356.
ORI found that Respondent engaged in research misconduct by intentionally falsifying and/or fabricating data reported in the following eight (8) published papers, one (1) unpublished manuscript, and one (1) NIH grant application:
J. Cell. Sci. 123:894-902, 2010 (hereafter referred to as "J. Cell. Sci. 2010a")
J. Cell. Sci. 123:4117-4127, 2010 (hereafter referred to as "J. Cell. Sci. 2010b")
J. Cell. Sci. 125:2995-3003, 2012 (hereafter referred to as "J. Cell. Sci. 2012")
J. Cell. Sci. 126:274-288, 2013 (hereafter referred to as "J. Cell. Sci. 2013")
J. Cell. Sci. 127:896-907, 2014 (hereafter referred to as "J. Cell. Sci. 2014")
Biol. Open. 1-11:10;bio.014712, 2015 (hereafter referred to as "Biol. Open. 2015")
BioChim Biophys Acta. 1827:38-49, 2013 (hereafter referred to as "BioChim Biophys Acta. 2013")
J. Biol. Chem. 289:26213-26225, 2014 (hereafter referred to as "J. Biol. Chem. 2014")
J. Cell. Science, Submitted manuscript, 2015 (hereafter referred to as "J. Cell. Sci. manuscript 2015")
R01 HL132672-01, "Regulation by Sirtuin-3 and Mitoneet of the Permeability Transition Pore in Heart during Ischemia/Reperfusion Injury," John Pastorino, Ph.D., Principal Investigator
ORI found that Dr. Pastorino falsified and/or fabricated Western
blot data for
mitochondrial function related to cell/tissue injury, in
fifty-eight (58) blot panels included in forty-two (42) figures in
eight (8) publications, one (1) unpublished manuscript, and one (1)
grant application. In the absence of valid Western blot images, the
Respondent fabricated and/or falsified quantitative data in
associated bar graphs, statistical analyses presented in figure
legends, and
related text.
Specifically, ORI found that Respondent duplicated images, or trimmed and/or manipulated blot images from unrelated sources to obscure their origin, and relabeled them to represent different experimental results in:
Figures 2A, 2C, 3B, 5A, 7B, and 8A in J. Cell. Sci. 2010a
Figures 2B, 5A, 6A, and 6B in J. Cell. Sci. 2010b
Figures 1A, 2A, 2B, 4C, 5A, 5B, 6A, 7A, 7B, and 7C in J. Cell. Sci. 2012
Figures 4F, 5H, and 6A in J. Cell. Sci. 2013
Figures 1B, 2B, 2C, 3A, 3B, and 4D in J. Cell. Sci. 2014
Figures 3A and 6B in Biol. Open 2015
Figure 2A in BioChim Biophys Acta. 2013
Figures 1B, 3A, 4D, 5E, and 6C in J. Biol. Chem. 2014
Figure 3A in J. Cell. Sci. manuscript 2015
Figures 3, 8A, 12, and 13A in R01 HL132672-01 NIH grant application
Dr. Pastorino has entered into a Voluntary Exclusion Agreement (Agreement) and has voluntarily agreed for a period of five (5) years, beginning on April 27, 2016:
(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as "covered transactions" pursuant to HHS' Implementation (2 CFR part 376 et seq.) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the "Debarment Regulations');
(2) that he will neither apply for nor permit his name to be
used on any application, proposal, or other request for funds to
the United States Government or any of its agencies, as defined in
the Debarment Regulations; Respondent will further ensure that
during the period of the voluntary exclusion, he will neither
receive nor be supported by funds of the United States Government
and its agencies made available through grants, subgrants,
cooperative agreements, contracts, or
subcontracts, as discussed in the Debarment Regulations; and
(3) to exclude himself from serving in any advisory capacity to the U.S. Public Health Service (PHS) including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.
Inquiries
Please direct all inquiries to:
Kathryn M. Partin
Director
Office of Research Integrity
1101 Wootton Parkway, Suite 750
Rockville, MD 20852
Telephone: 240-453-8800